Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab"
Liver Int
.
2024 May 8.
doi: 10.1111/liv.15964.
Online ahead of print.
Authors
Tatsuya Kikuchi
1
,
Yasuto Takeuchi
1
2
,
Kazuhiro Nouso
3
,
Kazuya Kariyama
3
,
Kenji Kuwaki
4
,
Junichi Toshimori
5
,
Shota Iwado
6
,
Akio Moriya
7
,
Hiroaki Hagihara
8
,
Hiroyuki Takabatake
9
,
Toshifumi Tada
10
,
Tetsuya Yasunaka
11
,
Masahiro Sakata
12
,
Masahiko Sue
1
,
Nozomi Miyake
1
,
Takuya Adachi
1
,
Nozomu Wada
1
,
Hideki Onishi
1
,
Hidenori Shiraha
1
,
Akinobu Takaki
1
,
Motoyuki Otsuka
1
Affiliations
1
Department of Gastroenterology and Hepatology, Okayama University Hospital, Okayama, Japan.
2
Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
3
Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
4
Department of Gastroenterology, Okayama Saiseikai General Hospital, Okayama, Japan.
5
Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
6
Department of Gastroenterology, Hiroshima City Hospital, Hiroshima, Japan.
7
Department of Gastroenterology, Mitoyo General Hospital, Kanonji, Japan.
8
Department of Gastroenterology, Sumitomo Besshi Hospital, Niihama, Japan.
9
Department of Gastroenterology, Kurashiki Central Hospital, Kurashiki, Japan.
10
Department of Gastroenterology, Japanese Red Cross Himeji Hospital, Himeji, Japan.
11
Department of Gastroenterology, Fukuyama City Hospital, Fukuyama, Japan.
12
Department of Gastroenterology, Fukuyama Medical Center, Fukuyama, Japan.
PMID:
38717049
DOI:
10.1111/liv.15964
No abstract available
Publication types
Letter
Grants and funding
22H02828/Ministry of Education, Culture, Sports, Science, and Technology
JP 23fk0210092/Japan Agency for Medical Research and Development
JP 23fk0210133/Japan Agency for Medical Research and Development
JP 23fk0310506/Japan Agency for Medical Research and Development